Kaistha B P, Honstein T, Müller V, Bielak S, Sauer M, Kreider R, Fassan M, Scarpa A, Schmees C, Volkmer H, Gress T M, Buchholz M
Department of Medicine, Division of Gastroenterology, Endocrinology and Metabolism, Philipps University Marburg, Marburg, Germany.
Dipartimento ad Attività Integrata (DAI) di Patologia e Diagnostica, University of Verona, Verona, Italy.
Br J Cancer. 2014 Oct 28;111(9):1780-7. doi: 10.1038/bjc.2014.460. Epub 2014 Aug 19.
Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive human malignancies with an overall 5-year survival rate of <5%. Despite significant advances in treatment of the disease during the past decade, the median survival rate (∼6 months) has hardly improved, warranting the need to identify novel targets for therapeutic approaches.
Quantitative real time PCR, western blot analyses and immunohistochemical staining of tissue microarrays were used to analyse the expression of TTK gene in primary PDAC tissues and cell lines. To inhibit TTK kinase expression in a variety of pancreatic cancer cell lines, RNA interference was used. Functional roles of this kinase in the context of PDAC were studied using cell proliferation, viability and anchorage-independent growth assays. Western blotting, fluorescence-activated cell sorting analyses and fluorescence microscopy were used to gain mechanistic insight into the functional effects.
We show that the dual specificity kinase TTK (also known as Mps1), is strongly overexpressed in human PDAC. Functionally, cell proliferation was significantly attenuated following TTK knockdown, whereas apoptosis and necrosis rates were significantly increased. In addition, anchorage-independent growth, a hallmark of malignant transformation and metastatic potential, was strongly impaired in the absence of TTK gene function. Interestingly, immortalised normal pancreatic hTERT-HPNE cells were not affected by loss of TTK function. Mechanistically, these effects in cancer cells were associated with increased formation of micronuclei, suggesting that loss of TTK function in pancreatic cancer cells results in chromosomal instability and mitotic catastrophe. Taken together, our data show that TTK function is critical for growth and proliferation of pancreatic cancer cells, thus establishing this kinase as an interesting new target for novel therapeutic approaches in combating this malignancy.
胰腺导管腺癌(PDAC)是最具侵袭性的人类恶性肿瘤之一,总体5年生存率小于5%。尽管在过去十年中该疾病的治疗取得了显著进展,但中位生存率(约6个月)几乎没有改善,因此有必要确定新的治疗靶点。
采用定量实时PCR、蛋白质免疫印迹分析和组织芯片免疫组化染色来分析原发性PDAC组织和细胞系中TTK基因的表达。为了在多种胰腺癌细胞系中抑制TTK激酶表达,采用了RNA干扰技术。使用细胞增殖、活力和非锚定依赖性生长试验研究了该激酶在PDAC中的功能作用。采用蛋白质免疫印迹、荧光激活细胞分选分析和荧光显微镜来深入了解其功能效应的机制。
我们发现双特异性激酶TTK(也称为Mps1)在人类PDAC中强烈过表达。在功能上,TTK基因敲低后细胞增殖显著减弱,而凋亡和坏死率显著增加。此外,非锚定依赖性生长作为恶性转化和转移潜能的标志,在缺乏TTK基因功能时受到强烈损害。有趣的是,永生化的正常胰腺hTERT-HPNE细胞不受TTK功能丧失的影响。从机制上讲,癌细胞中的这些效应与微核形成增加有关,这表明胰腺癌细胞中TTK功能丧失导致染色体不稳定和有丝分裂灾难。综上所述,我们的数据表明TTK功能对胰腺癌细胞的生长和增殖至关重要,从而将该激酶确立为对抗这种恶性肿瘤新治疗方法的一个有吸引力的新靶点。